Edward Wolin is an Oncology physician affiliated with Mount Sinai Medical Center. OpenAlex indexes 202 publications with 14,944 citations (h-index 39).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-6756Registry record last updated 21 Jul 2022.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20256 payments
- Medtronic, Inc.Program year20251 payment
- Telix PharmaceuticalsProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms100%Creon72%Zenpep28%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine
2024 - Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
Journal of Clinical Oncology
2021 - Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
European Journal of Nuclear Medicine and Molecular Imaging
2020
Similar KOLs
Other experts from the same institution or the same specialty.
David Nierman, MD
Mount Sinai Medical Center
Jaya Ganesh, MD
Mount Sinai Medical Center
Efsevia Albanis, MD
Mount Sinai Medical Center
Fenella Greig, MD
Mount Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”